Background: Organizations have a responsibility to reduce cognitive demands and strengthen health literacy support for patients and clients to improve understanding, access, and use of services. Most studies of organizational health literacy (OHL) are focused on traditional clinical settings and do not provide clear direction on how to make change. It is recognized that many people seek their everyday health information from trusted community-based organizations.
View Article and Find Full Text PDFClin Gastroenterol Hepatol
March 2025
Background: We aimed to describe the real-world effectiveness and safety of upadacitinib (UPA), an oral Janus kinase 1 inhibitor (JAKi) in patients with Crohn's disease (CD).
Methods: A retrospective analysis was conducted across nine centers in the United States, focusing on adults with CD treated with UPA 45 mg as induction therapy for active luminal disease. The co-primary endpoints were clinical remission at 12 weeks (Harvey Bradshaw Index ≤ 4 or absence of symptoms on physician's global assessment) and endoscopic remission at 6 months (SEMA-CD score of 0-1 or absence of ulcers).
Objective: To develop a reproducible ex vivo heart perfusion (EVHP) and murine heart transplantation model and to evaluate the efficacy of hypothermic, acellular ex vivo perfusion with sphingosine-1-phosphate (S1P) as a strategy to mitigate transplantation-associated ischemia-reperfusion injury (IRI).
Methods: Donor hearts from wild-type (WT) mice were stratified by preservation technique. Group 1 (n=4) hearts served as non-transplanted controls.
Importance: An important public health goal is to increase tobacco cessation, but there is limited research on associations of vaping with tobacco cessation.
Objective: To estimate the association of vaping with long-term tobacco cessation among US cigarette smokers who used electronic nicotine delivery systems (ENDS; ie, e-cigarettes) in 2017.
Design, Setting, And Participants: This cohort study used a nationally representative sample of US cigarette smokers from the Population Assessment of Tobacco and Health cohort at wave 4 (2017) with follow-up at wave 6 (2021).
We examined innate and antibody responses in C3PO clinical trial participants of COVID-19 convalescent plasma to identify predictors of disease progression. We found SARS-CoV-2 viremia in 64% of participants at enrollment, and we could also quantify viremia in approximately half of those samples using an RT-PCR assay. Viremia was associated with increased risk of disease progression (OR 3.
View Article and Find Full Text PDF